AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25178072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed irbesartan/amlodipine combination 150/5 mg
Number of subjects: 158
Study 25178072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed irbesartan/amlodipine combination 150/10 mg
Number of subjects: 158
Study 25178072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed irbesartan/amlodipine combination 300/5 mg
Number of subjects: 158
Study 25178072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed irbesartan/amlodipine combination 300/10 mg
Number of subjects: 158
Study 25178072 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with irbesartan/amlodipine combinations
Number of subjects: 158
Study 22412063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral hand treatment containing 2% citric acid and 2% malic acid in 62% ethanol (applied every 3 hours while awake)
Number of subjects: 212
Study 22412063 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 212
Study 22412063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral hand treatment
Number of subjects: 212
Study 20696083 — intervention group
Group type: EXPERIMENTAL
Intervention: Iota-Carrageenan nasal spray (0.12%) in saline solution, three times daily for 4 days
Number of subjects: 35
Study 18418290 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal washing 1 to 14 times/week
Number of subjects: 151
Study 18418290 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal washing 15 to 28 times/week
Number of subjects: 151
Study 18418290 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal washing >28 times/week
Number of subjects: 151
Study 18418290 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cloth for intravaginal cleansing
Number of subjects: 151
Study 18418290 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent unprotected intercourse
Number of subjects: 151
Study 18418290 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate contraception
Number of subjects: 151
Study 15669890 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone up to 6 mg/day
Number of subjects: 30
Study 15669890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15669890 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 30
Study 14507264 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBC units
Number of subjects: 531
Study 14507264 — intervention group
Group type: COMPARATOR
Intervention: Non-WBC-reduced RBC units
Number of subjects: 531
Study 10843300 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based reinforcement therapy (VBRT)
Number of subjects: 0
Study 10843300 — intervention group
Group type: COMPARATOR
Intervention: Yoked control condition
Number of subjects: 0
Study 8877926 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate 400 mg/day for 2 weeks followed by a 13 week drug-free period for a total of 120 weeks
Number of subjects: 37
Study 8877926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1687322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.1%
Number of subjects: 56
Study 1687322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.6%
Number of subjects: 56
Study 1687322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.1% to 0.6%
Number of subjects: 56
Study 6213330 — intervention group
Group type: EXPERIMENTAL
Intervention: Real plasmapheresis
Number of subjects: 9
Study 6213330 — intervention group
Group type: COMPARATOR
Intervention: Sham reinfusion plasmapheresis
Number of subjects: 9
Study 30173582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% supramolecular salicylic acid (2% SSA)
Number of subjects: 31
Study 30173582 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide + 0.1% adapalene (5%BPO +0.1%ADA)
Number of subjects: 31
Study 28629738 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/O2
Number of subjects: 140
Study 28629738 — intervention group
Group type: COMPARATOR
Intervention: Oral sedation (hydrocodone/acetaminophen and lorazepam)
Number of subjects: 140
Study 26211827 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 31920
Study 25063205 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein + carbohydrate (whey)
Number of subjects: 24
Study 25063205 — intervention group
Group type: COMPARATOR
Intervention: Iso-caloric carbohydrate (placebo)
Number of subjects: 24
Study 25063205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (whey and placebo)
Number of subjects: 24
Study 21981269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (HT)
Number of subjects: 24
Study 21981269 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (NT)
Number of subjects: 24
Study 20503800 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory steady-state response (ASSR)
Number of subjects: 16
Study 20503800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure-tone audiometric threshold (PTAT)
Number of subjects: 16
Study 20503800 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PTAT and ASSR
Number of subjects: 16
Study 17211861 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (35 mg/m2 on Days 1, 8, and 15 of a 4-week cycle) plus cisplatin (75 mg/m2 on Day 1)
Number of subjects: 86
Study 17211861 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel (75 mg/m2 on Day 1) plus cisplatin (75 mg/m2 on Day 1)
Number of subjects: 86
Study 15005790 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 0
Study 15005790 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 0
Study 11871190 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) at doses of 100 to 2000 micrograms daily
Number of subjects: 15
Study 11871190 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) at a two-fold increased dose
Number of subjects: 15
Study 9708454 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 117
Study 9708454 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 117
Study 9708454 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 117
Study 7611862 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐1 receptor antagonist (100 mg loading dose, followed by continuous infusion of 1.0 mg/kg per hour or 2.0 mg/kg per hour)
Number of subjects: 26
Study 7611862 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐1 receptor antagonist (high dose)
Number of subjects: 26
Study 7611862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2121574 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (200 mg)
Number of subjects: 37
Study 77369 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine skin preparation with 70% isopropyl alcohol for 5 seconds
Number of subjects: 13
Study 77369 — intervention group
Group type: COMPARATOR
Intervention: No skin preparation before insulin injection
Number of subjects: 13
Study 31419483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg plus azithromycin 2 g
Number of subjects: 143
Study 31419483 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg plus azithromycin 2 g
Number of subjects: 143
Study 31402005 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorination at the point of collection using solid tablet chlorine doser (treatment group)
Number of subjects: 920
Study 31402005 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C doser (active control group)
Number of subjects: 920
Study 28026906 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful H. pylori eradication therapy
Number of subjects: 743
Study 28026906 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire survey responses from patients
Number of subjects: 743
Study 25713437 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab plus dacarbazine
Number of subjects: 502
Study 25713437 — intervention group
Group type: COMPARATOR
Intervention: placebo plus dacarbazine
Number of subjects: 502
Study 23888317 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day of encapsulated fish oil (providing 600 mg/day of EPA + DHA) for 9 weeks
Number of subjects: 11
Study 23888317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 11
Study 21252589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 0
Study 21252589 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) turned off
Number of subjects: 0
Study 21252589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative testing after placement of the STN deep brain stimulator
Number of subjects: 0
Study 18046534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin (40 mg/kg)
Number of subjects: 6
Study 18046534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin (50 mg/kg)
Number of subjects: 6
Study 18046534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin (60 mg/kg)
Number of subjects: 6
Study 18046534 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amikacin (15 mg/kg)
Number of subjects: 6
Study 16834877 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-patient testing for glycated haemoglobin (HbA1c)
Number of subjects: 681
Study 16834877 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 681
Study 16834877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of diabetes-related care for intervention group
Number of subjects: 681
Study 16834877 — intervention group
Group type: COMPARATOR
Intervention: Cost of diabetes-related care for control group
Number of subjects: 681
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 U of BTX‐A injected into the lower eyelid bilaterally and 12 U injected into one lateral orbital area.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 U of BTX‐A injected bilaterally into the lower eyelid and 12 U placed unilaterally into the crow's feet.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 U of BTX‐A injected into the lower eyelid alone.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 U of BTX‐A injected into the lower eyelid alone.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 U of BTX‐A in the lower eyelid plus 12 U in the lateral orbital area.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 U of BTX‐A in the lower eyelid plus 12 U in the lateral orbital area.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 U of BTX‐A in the lower eyelid alone.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 U of BTX‐A in the lower eyelid alone.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 U in the bilateral orbital area plus 4 U in the lower eyelid.
Number of subjects: 19
Study 12930337 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 U in the lower lid plus the crow's feet.
Number of subjects: 19
Study 10936473 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb compression bandage (e.g., Unna's boot) applied weekly
Number of subjects: 185
Study 8952671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 1003
Study 8952671 — intervention group
Group type: COMPARATOR
Intervention: Placebo or Azathioprine
Number of subjects: 1003
Study 1384143 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine)
Number of subjects: 0
Study 1384143 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine/vincristine/procarbazine/prednisone)
Number of subjects: 0
Study 3903784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g triletide per day
Number of subjects: 30
Study 3903784 — intervention group
Group type: COMPARATOR
Intervention: 1.6 g aluminium hydroxide and 1.6 g magnesium hydroxide per day
Number of subjects: 30
Study 30540640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus group
Number of subjects: 66
Study 30540640 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion group
Number of subjects: 66
Study 30540640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 30567725 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/m2 of IV decitabine on days 1 to 10
Number of subjects: 64
Study 30567725 — intervention group
Group type: COMPARATOR
Intervention: 1.3 mg/m2 of subcutaneous bortezomib on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles
Number of subjects: 64
Study 30567725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of decitabine and bortezomib
Number of subjects: 64
Study 26857443 — intervention group
Group type: EXPERIMENTAL
Intervention: Solubilized vaginal estradiol softgel capsule (TX-004HR) at 10-μg
Number of subjects: 71
Study 26857443 — intervention group
Group type: EXPERIMENTAL
Intervention: Solubilized vaginal estradiol softgel capsule (TX-004HR) at 25-μg
Number of subjects: 71
Study 26857443 — intervention group
Group type: COMPARATOR
Intervention: Vaginal estradiol tablet (Vagifem®) at 10-μg
Number of subjects: 71
Study 26857443 — intervention group
Group type: COMPARATOR
Intervention: Vaginal estradiol tablet (Vagifem®) at 25-μg
Number of subjects: 71
Study 24397408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 6
Study 24397408 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 6
Study 24397408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 22916547 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Life and HIV Education (FLHE) programme
Number of subjects: 0
Study 22916547 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Life and HIV Education (FLHE) programme and community programme
Number of subjects: 0
Study 22916547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19238517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 325 mg
Number of subjects: 30
Study 19238517 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid 1,250 mg
Number of subjects: 30
Study 19238517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17410456 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP) weekly for 5 weeks
Number of subjects: 20
Study 17410456 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP) monthly after initial treatment
Number of subjects: 20
Study 17410456 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control) after initial remission
Number of subjects: 20
Study 15369805 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (1 microM)
Number of subjects: 0
Study 11600586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg/d)
Number of subjects: 24
Study 11600586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4000 mg/d)
Number of subjects: 24
Study 11600586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9706882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical model predicting survival
Number of subjects: 1145
Study 9706882 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I model predictions
Number of subjects: 1145
Study 9706882 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II model predictions
Number of subjects: 1145
Study 9706882 — intervention group
Group type: EXPERIMENTAL
Intervention: AFT and PH survival models
Number of subjects: 1145
Study 8282330 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalkiren
Number of subjects: 18
Study 8282330 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 18
Study 8282330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8282330 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (Ang II) infusion
Number of subjects: 18
Study 2564357 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380Ag
Number of subjects: 198
Study 2564357 — intervention group
Group type: COMPARATOR
Intervention: Cu-7
Number of subjects: 198
Study 30395791 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged4Life program (technology-assisted self-monitoring of daily activity via pedometers and daily tablet-based surveys; psychoeducation + goal-setting via a 3-hour workshop; peer mentoring via phone 2×/week for 2.5 weeks)
Number of subjects: 30
Study 30395791 — intervention group
Group type: COMPARATOR
Intervention: Control group (technology-assisted self-monitoring only)
Number of subjects: 30
Study 28978327 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone/prednisone with continuing LHRH therapy
Number of subjects: 0
Study 28978327 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone/prednisone with LHRH withdrawal
Number of subjects: 0
Study 26704701 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg OD
Number of subjects: 3184
Study 26704701 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 μg OD
Number of subjects: 3184
Study 26704701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3184
Study 26704701 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 3184
Study 26704701 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 μg
Number of subjects: 3184
Study 26704701 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram assessments
Number of subjects: 3184
Study 26704701 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h urinary cortisol excretion
Number of subjects: 3184
Study 23209276 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment (160 mg daily) until the day before CABG
Number of subjects: 20
Study 23209276 — intervention group
Group type: COMPARATOR
Intervention: No ASA treatment (withdrawal 7 days before surgery)
Number of subjects: 20
Study 23209276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during surgery
Number of subjects: 20
Study 23209276 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA treatment
Number of subjects: 20
Study 23209276 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Number of subjects: 20
Study 21515871 — intervention group
Group type: EXPERIMENTAL
Intervention: FES with intramuscular (IM) electrodes (FES‐IM)
Number of subjects: 53
Study 21515871 — intervention group
Group type: COMPARATOR
Intervention: No‐FES
Number of subjects: 53
Study 17208117 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult RCTs
Number of subjects: 0
Study 17208117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric RCTs
Number of subjects: 0
Study 15045501 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Nottingham Power Rig (mNPR)
Number of subjects: 9
Study 15045501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 9
Study 15045501 — intervention group
Group type: COMPARATOR
Intervention: Comparison between mNPR and cycling
Number of subjects: 9
Study 12642991 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated interventions
Number of subjects: 0
Study 12642991 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9659350 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled L-arginine 3 g
Number of subjects: 43
Study 9659350 — intervention group
Group type: COMPARATOR
Intervention: Inhaled L-alanine 3 g
Number of subjects: 43
Study 10150184 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 49
Study 10150184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 2582827 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI)
Number of subjects: 18
Study 2582827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer (NEB)
Number of subjects: 18
Study 2582827 — intervention group
Group type: COMPARATOR
Intervention: MDI and NEB
Number of subjects: 18
Study 766555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg daily for 14 days)
Number of subjects: 38
Study 766555 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilboestrol (20 mg daily for 7 days followed by placebo for 7 days)
Number of subjects: 38
Study 766555 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 women not receiving any medication)
Number of subjects: 38
Study 29642199 — intervention group
Group type: EXPERIMENTAL
Intervention: Study protocol (tube voltage adaptation and iterative reconstructions)
Number of subjects: 112
Study 29642199 — intervention group
Group type: COMPARATOR
Intervention: Reference protocol (120 kV with tube current modulation)
Number of subjects: 112
Study 29137111 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-DHA (400 mg/day)
Number of subjects: 4837
Study 29137111 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA (2 g/day)
Number of subjects: 4837
Study 29137111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EPA-DHA and ALA
Number of subjects: 4837
Study 29137111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4837
Study 25762858 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based employment services (job development or placement and employment follow-along or supports)
Number of subjects: 81
Study 25762858 — intervention group
Group type: COMPARATOR
Intervention: Office-based vocational counseling services
Number of subjects: 81
Study 23250912 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate (highest vs. lowest distribution third)
Number of subjects: 4084
Study 23250912 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate (after adjustment for IL‐6 and vWf levels)
Number of subjects: 4084
Study 21244606 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of tadalafil once daily
Number of subjects: 427
Study 18434839 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartPlug
Number of subjects: 36